In this 2-part animated video series, GU cancer genomics expert Dr Alexander Wyatt and pathologist Prof. Frédéric Bibeau share their recommendations and tips on how to optimise genomic testing in prostate cancer and gastric cancer.

 

Each video comes with an accompanying slide set that you can download for more information.

In this 2-part animated video series, GU cancer genomics expert Dr Alexander Wyatt and pathologist Prof. Frédéric Bibeau share their recommendations and tips on how to optimise genomic testing in prostate cancer and gastric cancer.

 

Each video comes with an accompanying slide set that you can download for more information.

In this animated video, GU cancer genomics expert Dr Alexander Wyatt shares recommendations from the guidelines, and his best tips for optimising precision oncology in prostate cancer.

 

Multi-gene germline and somatic testing is required for the identification of gene alterations in advanced prostate cancer. Both tissue and liquid biopsy (ctDNA) can be used for somatic testing, but it’s important for HCPs to know when to use liquid biopsy and how to conserve the quality of tissue samples.

 

Dr Wyatt addresses these questions and highlights other key points, including:

  • Common genomic alterations and implications in prostate cancer
  • When to order biomarker testing
  • Samples that can be used for somatic and germline testing
  • Potential challenges and recommendations to reduce the limitations of testing and interpreting results

 

Clinical takeaways

  • It is important to consider that different types of samples are needed for somatic and germline testing
  • Genomic biomarker testing is required to help with treatment decision making and for understanding inherited cancer risk
  • Next-generation sequencing of multiple genes is the gold-standard method for both germline and tumour (somatic) testing in prostate cancer
  • Alterations in HRR genes and MMR pathway genes in advanced prostate cancer can predict response to targeted therapies
  • Know how to navigate pre-analytical phase challenges, including how to collect, store, process and prepare the samples
  • Be able to include all relevant biomarkers in the test request and tests​
  • Understand the diagnostic modalities, and the role of biomarkers in oncology​
  • Be able to implement or improve the leading role of the pathologist on the MDT​

Dr. Wyatt is an associate professor in Urologic Sciences at the University of British Columbia, Canada. He is a senior research scientist at the Vancouver Prostate Centre and a senior scientist at BC Cancer. Dr. Wyatt has a DPhil in genetics from the University of Oxford. His research goals are to identify associations between genomic alterations and patient outcomes in metastatic prostate and bladder cancer, and to translate these findings into clinical biomarkers. Dr. Wyatt has developed novel laboratory and computational techniques to study plasma circulating tumour DNA (ctDNA). Through application of these methods to clinical trial cohorts, his team has demonstrated that ctDNA is highly representative of metastatic lesions, and that somatic alterations detected in ctDNA can help predict prostate cancer therapy resistance or response.

In this animated video, expert Prof. Frédéric Bibeau shares the guideline recommendations and best tips for precision oncology in gastric cancer, including: 

  • Relevant biomarkers and implications in gastric cancer
  • Who, when, and how to order biomarker testing
  • Techniques that are used for biomarker testing in gastric cancer
  • Challenges and recommendations to optimise biomarker assessment

 

Clinical takeaways

  • It is paramount to have enough samples to perform all the tests needed, starting with diagnosis
  • Order the right biomarkers to help with treatment decision-making
  • In gastric cancer, the use of IHC and ISH are the main techniques for precision medicine in 2024
  • HER2 status, PD-L1 and MMR are crucial for treatment decisions in 2024
  • Know how to navigate pre-analytical phase challenges, including how to collect, store, process and prepare the samples​ 
  • Be able to include all relevant biomarkers in the test request and tests​ 
  • Understand the diagnostic modalities, and the role of biomarkers in oncology​ 
  • Be able to implement or improve the leading role of the pathologist on the MDT​ 

Frédéric Bibeau, MD, PhD, is a Professor of Pathology at the head of the Pathology Department of the Besançon University Hospital, Franche-Comté University. He is involved in translational research, in immuno-oncology of solid tumors and in gastrointestinal tumor pathology, notably colorectal cancer, both at the diagnostic and research levels. He is responsible for several long courses in pathology and molecular pathology, notably of the GI tract. Since ten years his work has been focused on rectal cancer, microsatellite unstable colorectal cancer, liver metastases after induction treatment, peritoneal carcinomatosis and predictive factors linked to targeted therapies and immunotherapy. He also involved in national and international groups specialized in rare tumors of the peritoneum. He was one of two coordinators of the BIG-RENAPE network, corresponding to a biological and clinical database dedicated to peritoneal carcinomatosis of digestive origin.

Professor Bibeau is author or co-author of 213 publications. He belongs to the board of national and international journals. He is a member of the French Society of Pathology, the International Academy of Pathology, the French Federation of Digestive Oncology (FFCD). He has been an active member of the European Society of Medical Oncology (ESMO) and the ESMO-Precision-Medicine working group.

Prof. Frédéric Bibeau has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Amgen, MSD and Sanofi. 

 

Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4
Programme summary
Watch the video now
Share this programme
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from AstraZeneca and Amoy Diagnostics.
Endorsement
I agree that this educational programme:

Was valuable to me

1/4

Other programmes of interest

conference-update Conference update
Oncology 
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium

Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer  

Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Σειρά podcast για τη διαχείριση της θρόμβωσης

Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial

How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?

Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from AstraZeneca
podcast Podcast
Oncology Obstetrics and Gynecology 
Advanced or recurrent endometrial cancer: Molecular classification and treatment decisions

Understanding the role of molecular subtypes in guiding treatment selection

Experts
Prof. Xavier Matias-Guiu, Dr Jurjees Hasan
Endorsed by
Biomarker Collaborative ICAN international cancer advocacy network
  • download Downloadable
    Resources
  • clock 11 MIN
  • calendar Feb 2025

This programme has been sponsored by Eisai Europe Limited ("Eisai"). Eisai has had no input on the educational content of, or speakers involved in this Video Podcast.
podcast Podcast
Hemostasis and bleeding disorders Oncology 
Postępowanie w przypadku zakrzepicy – seria podcastów

Uznani eksperci dzielą się swoimi spostrzeżeniami. Kliknij na odpowiednią zakładkę, aby wybrać odcinek podcastu.

Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga
  • download Downloadable
    Resources
  • clock 27 MIN
  • calendar Feb 2025

This educational programme is supported by an Independent Educational Grant from Viatris.
conference-update Conference update
Oncology 
Highlights from ASCO GI 2025

Expert insights on BRAF-mutated colorectal cancer

Experts
Dr Elena Élez
Endorsed by
DiCE BRAF Bombers ICAN international cancer advocacy network
Biomarker Collaborative
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Feb 2025

Educational programme supported by an Independent Educational Grant from Pierre Fabre Laboratories. The programme is therefore independent, the content is not influenced by Pierre Fabre Laboratories and is under the sole responsibility of the experts. This content is intended for HCPs outside the UK and ROl only.